ReviewDrugs2016
Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03899246 (Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Different Acupuncture Therapies for Postherpetic Neuralgia: An Overview of Systematic Reviews and Meta-analysis.Chinese journal of integrative medicine · 2025Pooled it
- Topical capsaicin (high concentration) for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Cooling the burn: EMLA alone vs. paravertebral block plus EMLA for improving tolerability of 8% capsaicin patch application in thoracic postherpetic neuralgia-a retrospective cohort study.Frontiers in aging neuroscience · 2026Article
- Pathophysiology-Directed Engineering of a Combination Nanoanalgesic for Neuropathic Pain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Spinal neuron-glial crosstalk and ion channel dysregulation in diabetic neuropathic pain.Frontiers in immunology · 2025Review
- Anticancer Activity of Region B Capsaicin Analogs.Journal of medicinal chemistry · 2023Review
- Capsaicin 8% Patch and Chronic Postsurgical Neuropathic Pain.Journal of personalized medicine · 2021Review
- The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients.Journal of diabetes and metabolic disorders · 2021Article
- Expert consensus of the Chinese Association for the Study of Pain on pain treatment with the transdermal patch.World journal of clinical cases · 2021Review
- Desensitization of Capsaicin-Sensitive Afferents Accelerates Early Tumor GrowthFrontiers in oncology · 2021Article
- Novel Agents in Neuropathic Pain, the Role of Capsaicin: Pharmacology, Efficacy, Side Effects, Different Preparations.Current pain and headache reports · 2020Review
- Novel Analgesics with Peripheral Targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Review
- Nitrogen Source Affects the Composition of Metabolites in Pepper (Foods (Basel, Switzerland) · 2020Article
- Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research.Frontiers in pharmacology · 2020Review
- Novel TRPV1 Channel Agonists With Faster and More Potent Analgesic Properties Than Capsaicin.Frontiers in pharmacology · 2020Article
- Expert Opinion: Exploring the Effectiveness and Tolerability of Capsaicin 179 mg Cutaneous Patch and Pregabalin in the Treatment of Peripheral Neuropathic Pain.Journal of pain research · 2020Article
- Capsaicin: Physicochemical properties, cutaneous reactions and potential applications in painful and inflammatory conditions.Experimental and therapeutic medicine · 2019Review
- Assessment of Pharmacology, Safety, and Metabolic activity of Capsaicin Feeding in Mice.Scientific reports · 2019Article
- An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The capsaicin 8 % patch (QUTENZA®) is an adhesive patch containing a high concentration (8 % w/w) of synthetic capsaicin, a selective agonist of transient receptor potential vanilloid 1 channel. It is approved for treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain in the EU; it is only approved to treat postherpetic neuralgia (PHN) in the USA. In patients with painful diabetic peripheral neuropathy (PDPN), a single 30-min application of the capsaicin 8 % patch significantly improved pain relief and sleep quality compared with placebo in a 12-week double-blind trial. In a 52-week, randomized trial, up to seven consecutive 30-min treatments with the capsaicin 8 % patch (≤7 treatments each at least 8 weeks apart) plus standard of care therapy was associated with sustained pain relief and no negative neurological safety consequences compared with standard of care. In two randomized trials, a single 60-min application of the capsaicin 8 % patch reduced pain scores significantly more than a low-concentration (0.04 %) capsaicin control patch in patients with PHN. Capsaicin 8 % patch treatment was noninferior to pregabalin (optimized dosage) in a randomized trial in patients with nondiabetic peripheral neuropathic pain. Results in two trials in patients with HIV-AN were equivocal, with a significant improvement in pain intensity observed in one trial, but not in the other. The capsaicin 8 % patch was associated with expected, transient, capsaicin-related application-site adverse events such as erythema and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.